Top

BMC Cancer

Published in:

Open Access 01-12-2019 | Human Papillomavirus | Research article

Factors associated with low adherence to cervical cancer follow-up retest among HPV+/ cytology negative women: a study in programmatic context in a low-income population in Argentina

Authors: Juan Gago, Melisa Paolino, Silvina Arrossi

Published in: BMC Cancer | Issue 1/2019

Abstract

Background

Cervical Cancer is still a major public health challenge in low and middle-income countries. HPV testing has been an innovative approach, which was introduced in Argentina for women aged 30+ through the Jujuy Demonstration Project (JDP) carried out between 2012 and 2014. After a positive HPV-test, cytology is used as triage method. Under this protocol, the group of women with HPV+ and normal cytology are recommended to repeat the test within 12–18 months. Studies have shown that this group has increased risk of CIN2+, however, assuring high levels of repeating test among these women is difficult to achieve. We analyze those factors associated with lower re-test attendance among HPV+/ cytology negative women at a programmatic level in low-middle income settings.

Methods

We used data of women aged 30+ HPV-tested in the JDP and followed until 2018 (n = 49,565). We performed a set of different adjusted logistic regression models.

Primary outcomes were re-test attendance and re-test attendance within recommended timeframe. We assessed as covariates age, health insurance status, year of HPV-testing, Pap testing in the past 3 years, HPV-testing modality (clinician-collected (CC) tests/self-collected (SC) tests), and span between HPV-test collection and report of results.

Results

Forty nine thousand five hundred sixty five women were HPV-tested and 6742 had a positive HPV-test. Among HPV+ women, a total of 4522 were HPV+/Cytology negative (67.1%). In total, 3172 HPV+/Cytology negative women (70.1%) had a record of a second HPV test as of March 2018. Only 1196 women (26%) completed the second test within the timeframe. Women with no record of a previous Pap (OR: 0.46, 95% CI: 0.4–0.53, p < 0.001), aged 64+ (OR: 0.46, 95% CI: 0.31-0.68, p < 0.001) were less likely to be retested; while women with clinician-collected samples had higher odds of being re-tested (OR: 1.42, 95% CI: 1.06–1.91, p < 0.001).

Conclusions

Low re-test rates were found in HPV +/ normal cytology women. Tailored interventions are needed to increase the effectiveness of the screening in this group, especially for those women with characteristics associated to lower attendance.

Arrossi S, Paolino M, Sankaranarayanan R. Challenges faced by cervical cancer prevention programs in developing countries: a situational analysis of program organization in Argentina. Rev Panam Salud Publica. 2010;28(4):249–57.CrossRef

Franco EL, Cuzick J, Hildesheim A, de Sanjose S. Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine. 2006;24:171–7. https://doi.org/10.1016/j.vaccine.2006.05.061.CrossRef

Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009;360(14):1385–94. https://doi.org/10.1056/NEJMoa0808516.CrossRefPubMed

Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008;26(Suppl 10):K29–41. https://doi.org/10.1016/j.vaccine.2008.06.019.CrossRefPubMed

WHO. Comprehensive cervical cancer control: A guide to essential practice: WHO. http://www.who.int/cancer/publications/9241547006/en/. Accessed 25 Sept 2018.

Bergeron C, Giorgi-Rossi P, Cas F, et al. Informed cytology for triaging HPV-positive women: substudy nested in the NTCC randomized controlled trial. J Natl Cancer Inst. 2015;107(2). https://doi.org/10.1093/jnci/dju423.

Arrossi S, Thouyaret L, Paul L. Prevención del cáncer cervicouterino: recomendaciones para el tamizaje, seguimiento y tratamiento de mujeres en el marco de programas de tamizaje basados en el test de VPH. Actualización. Buenos Aires, Ministerio de Salud: 2015;20.

Polman NJ, Veldhuijzen NJ, Heideman DAM, Snijders PJF, Meijer CJLM, Berkhof J. HPV-positive women with normal cytology remain at increased risk of CIN3 after a negative repeat HPV test. Br J Cancer. 2017;117(10):1557–61. https://doi.org/10.1038/bjc.2017.309.CrossRefPubMedPubMedCentral

Uijterwaal MH, Polman NJ, Witte BI, et al. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data. Int J Cancer. 2015;136(10):2361–8. https://doi.org/10.1002/ijc.29290.CrossRefPubMed

10.

Rijkaart DC, Berkhof J, van Kemenade FJ, et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer. 2012;130(3):602–10. https://doi.org/10.1002/ijc.26056.CrossRefPubMed

11.

Alba LH, Díaz S, Gamboa O, et al. Accuracy of mammography and clinical breast examination in the implementation of breast cancer screening programs in Colombia. Prev Med. 2018;115:19–25. https://doi.org/10.1016/j.ypmed.2018.08.005.CrossRefPubMed

12.

Gage JC, Schiffman M, Katki HA, et al. Reassurance against future risk of Precancer and Cancer conferred by a negative human papillomavirus test. J Natl Cancer Inst. 2014;106(8). https://doi.org/10.1093/jnci/dju153.

13.

Anhang Price R, Zapka J, Edwards H, Taplin SH. Organizational factors and the cancer screening process. J Natl Cancer Inst Monogr. 2010;2010(40):38–57. https://doi.org/10.1093/jncimonographs/lgq008.CrossRefPubMedPubMedCentral

14.

Arrossi S, Paolino M, Laudi R, et al. Effect of programmatic HPV-testing in Cervical Cancer Prevention in the Jujuy Demonstration Project in Argentina: a Population-based, Quasi-experimental, Before and After Retrospective Cohort Study. Lancet Global Health. 2019; In Press.

15.

Arrossi S, Thouyaret L, Herrero R, et al. Effect of self-collection of HPV DNA offered by community health workers at home visits on uptake of screening for cervical cancer (the EMA study): a population-based cluster-randomised trial. Lancet Glob Health. 2015;3(2):e85–94. https://doi.org/10.1016/S2214-109X(14)70354-7.CrossRefPubMed

16.

Arrossi S, Paolino M, Thouyaret L, Laudi R, Campanera A. Evaluation of scaling-up of HPV self-collection offered by community health workers at home visits to increase screening among socially vulnerable under-screened women in Jujuy Province, Argentina. Implement Sci. 2017;12. https://doi.org/10.1186/s13012-017-0548-1.

17.

Burger EA, Pedersen K, Sy S, Kristiansen IS, Kim JJ. Choosing wisely: a model-based analysis evaluating the trade-offs in cancer benefit and diagnostic referrals among alternative HPV testing strategies in Norway. Br J Cancer. 2017;117(6):783–90. https://doi.org/10.1038/bjc.2017.248.CrossRefPubMedPubMedCentral

18.

Wiesner C, Cendales R, Murillo R, Piñeros M, Tovar S. Following-up females having an abnormal pap smear in Colombia. Rev Salud Publica Bogota. 2010;12(1):1–13.CrossRef

19.

Rendle KA, Schiffman M, Cheung LC, et al. Adherence patterns to extended cervical screening intervals in women undergoing human papillomavirus (HPV) and cytology cotesting. Prev Med. 2018;109:44–50. https://doi.org/10.1016/j.ypmed.2017.12.023.CrossRefPubMed

20.

Pasquale L, Giorgi Rossi P, Carozzi F, et al. Cervical cancer screening with HPV testing in the Valcamonica (Italy) screening programme. J Med Screen. 2015;22(1):38–48. https://doi.org/10.1177/0969141314561707.CrossRefPubMed

21.

Passamonti B, Gustinucci D, Giorgi Rossi P, et al. Cervical human papilloma virus (HPV) DNA primary screening test: results of a population-based screening programme in Central Italy. J Med Screen. 2017;24(3):153–62. https://doi.org/10.1177/0969141316663580.CrossRefPubMed

22.

Rebolj M, Bonde J, Preisler S, Ejegod D, Rygaard C, Lynge E. Human papillomavirus assays and cytology in primary cervical screening of women aged 30 years and above. PLoS One. 2016;11(1):e0147326. https://doi.org/10.1371/journal.pone.0147326.CrossRefPubMedPubMedCentral

23.

National Center for Health Statistics (US). Health, United States, 2016: With Chartbook on Long-Term Trends in Health. Hyattsville (MD): National Center for Health Statistics (US); 2017. http://www.ncbi.nlm.nih.gov/books/NBK453378/. Accessed 18 Sept 2018

24.

Watson M, Benard V, King J, Crawford A, Saraiya M. National assessment of HPV and pap tests: changes in cervical cancer screening, National Health Interview Survey. Prev Med. 2017;100:243–7. https://doi.org/10.1016/j.ypmed.2017.05.004.CrossRefPubMedPubMedCentral

25.

Musselwhite LW, Oliveira CM, Kwaramba T, et al. Racial/ethnic disparities in cervical Cancer screening and outcomes. Acta Cytol. 2016;60(6):518–26. https://doi.org/10.1159/000452240.CrossRefPubMed

26.

Chorley AJ, Marlow LAV, Forster AS, Haddrell JB, Waller J. Experiences of cervical screening and barriers to participation in the context of an organised programme: a systematic review and thematic synthesis. Psychooncology. 2017;26(2):161–72. https://doi.org/10.1002/pon.4126.CrossRefPubMed

27.

Melnikow J, Henderson JT, Burda BU, Senger CA, Durbin S, Soulsby MA. Screening for Cervical Cancer With High-Risk Human Papillomavirus Testing: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Rockville: Agency for Healthcare Research and Quality (US); 2018. http://www.ncbi.nlm.nih.gov/books/NBK526306/. Accessed 5 Nov 2018.CrossRef

28.

Paolino M, Arrossi S. Analysis of the reasons for abandoning the follow-up and treatment process in women with pre-cancerous cervical lesions in the province of Jujuy: implications for health management. Salud Colect. 2012;8(3):247–61. https://doi.org/10.1590/S1851-82652012000400003.CrossRefPubMed

29.

Dzuba IG, Calderón R, Bliesner S, Luciani S, Amado F, Jacob M. A participatory assessment to identify strategies for improved cervical cancer prevention and treatment in Bolivia. Rev Panam Salud Publica. 2005;18(1):53–63.CrossRef

30.

Paolino M, Sankaranarayanan R, Arrossi S. Social determinants of dropout from diagnosis and treatment by women with abnormal pap smears in Buenos Aires, Argentina. Rev Panam Salud Publica. 2013;34(6):437–45.PubMed

31.

Paz-Soldán VA, Bayer AM, Nussbaum L, Cabrera L. Structural barriers to screening for and treatment of cervical cancer in Peru. Reprod Health Matters. 2012;20(40). https://doi.org/10.1016/S0968-8080(12)40680-2.

32.

Luque JS, Tarasenko YN, Chen C. Correlates of cervical Cancer screening adherence among women in the U.S.: findings from HINTS 2013–2014. J Prim Prev. 2018;39(4):329–44. https://doi.org/10.1007/s10935-018-0513-z.CrossRefPubMed

33.

Li N, Hang D, Yang L, et al. Persistence of type-specific human papillomavirus infection among Daqing City women in China with normal cytology: a pilot prospective study. Oncotarget. 2017;8(46):81455–61. https://doi.org/10.18632/oncotarget.20188.CrossRefPubMedPubMedCentral

34.

Beavis AL, Gravitt PE, Rositch AF. Hysterectomy-corrected cervical cancer mortality rates reveal a larger racial disparity in the United States. Cancer. 2017;123(6):1044–50. https://doi.org/10.1002/cncr.30507.CrossRefPubMed

35.

Skaznik-Wikiel ME, Sukumvanich P, Austin RM, et al. Heavy cervical cancer burden in elderly women: how can we improve the situation? Acta Cytol. 2012;56(4):388–93. https://doi.org/10.1159/000338555.CrossRefPubMed

36.

Arrossi S, Ramos S, Straw C, Thouyaret L, Orellana L. HPV testing: a mixed-method approach to understand why women prefer self-collection in a middle-income country. BMC Public Health. 2016;16:832. https://doi.org/10.1186/s12889-016-3474-2.CrossRefPubMedPubMedCentral

37.

Gage JC, Ferreccio C, Gonzales M, Arroyo R, Huivín M, Robles SC. Follow-up care of women with an abnormal cytology in a low-resource setting. Cancer Detect Prev. 2003;27(6):466–71.CrossRef

38.

Arrossi S, Paolino M, Orellana L, Thouyaret L, Kohler RE, Viswanath K. Mixed-methods approach to evaluate an mHealth intervention to increase adherence to triage of human papillomavirus-positive women who have performed self-collection (the ATICA study): study protocol for a hybrid type I cluster randomized effectiveness-implementation trial. Trials. 2019;20(1):148. https://doi.org/10.1186/s13063-019-3229-3.CrossRefPubMedPubMedCentral

Title: Factors associated with low adherence to cervical cancer follow-up retest among HPV+/ cytology negative women: a study in programmatic context in a low-income population in Argentina
Authors: Juan Gago
Melisa Paolino
Silvina Arrossi
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Human Papillomavirus
Triage
Cervical Cancer
Cervical Cancer
Published in: BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-019-5583-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

Novel significant stage-specific differentially expressed genes in hepatocellular carcinoma

Molecular subtyping improves prognostication of Stage 2 colorectal cancer

Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis

microRNA-21 promotes breast cancer proliferation and metastasis by targeting LZTFL1

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer